Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations

Background Levodopa-carbidopa intestinal gel infusion (LCIG) is a therapeutic option for advanced Parkinson disease (PD) patients with troublesome motor complications, unresponsive to conventional oral treatment. There is some evidence to suggest that the genetic background may influence the clinica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurological sciences 2024-04, Vol.45 (4), p.1489-1497
Hauptverfasser:	Balestrino, R., Martone, T., Toffoli, M., Montanaro, E., Fabbri, M., Artusi, C. A., Romagnolo, A., Zibetti, M., Rizzone, M., Goldwurm, S., Lopiano, L., Schapira, A. H. V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Brain-derived neurotrophic factor Cognitive ability Deep brain stimulation Gene polymorphism Genetic screening Intestine Levodopa LRRK2 protein Medicine Medicine & Public Health Movement disorders Mutation Neurodegenerative diseases Neurology Neuropsychology Neuroradiology Neurosurgery Original Article Parkinson's disease Patients Psychiatry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!